Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:IMNM NASDAQ:KRYS NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$80.74-1.4%$78.54$32.89▼$88.31$10.05B0.422.06 million shs1.64 million shsIMNMImmunome$22.21+0.9%$21.02$8.66▼$27.65$2.52B2.071.46 million shs615,071 shsKRYSKrystal Biotech$335.19+2.3%$333.77$130.50▼$382.54$9.88B0.5585,251 shs520,339 shsNUVLNuvalent$123.96$115.86$71.13▼$123.99$9.79B1.141.93 million shsN/AThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics0.00%+0.70%-0.07%+23.61%+112.87%IMNMImmunome0.00%-0.49%+14.48%-5.73%+93.97%KRYSKrystal Biotech0.00%-5.54%-6.87%+23.00%+118.72%NUVLNuvalent0.00%0.00%+0.35%+18.62%+54.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$80.74-1.4%$78.54$32.89▼$88.31$10.05B0.422.06 million shs1.64 million shsIMNMImmunome$22.21+0.9%$21.02$8.66▼$27.65$2.52B2.071.46 million shs615,071 shsKRYSKrystal Biotech$335.19+2.3%$333.77$130.50▼$382.54$9.88B0.5585,251 shs520,339 shsNUVLNuvalent$123.96$115.86$71.13▼$123.99$9.79B1.141.93 million shsN/AThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics0.00%+0.70%-0.07%+23.61%+112.87%IMNMImmunome0.00%-0.49%+14.48%-5.73%+93.97%KRYSKrystal Biotech0.00%-5.54%-6.87%+23.00%+118.72%NUVLNuvalent0.00%0.00%+0.35%+18.62%+54.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.91Moderate Buy$99.9023.73% UpsideIMNMImmunome 2.86Moderate Buy$33.1749.33% UpsideKRYSKrystal Biotech 2.83Moderate Buy$360.677.60% UpsideNUVLNuvalent 2.15Hold$127.733.04% UpsideCurrent Analyst Ratings BreakdownLatest IMNM, CYTK, NUVL, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026IMNMImmunome WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$31.007/17/2026CYTKCytokinetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026IMNMImmunome Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026KRYSKrystal Biotech Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$364.00 ➝ $396.007/13/2026KRYSKrystal Biotech Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$474.007/9/2026IMNMImmunome CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/9/2026IMNMImmunome HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/7/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$119.00 ➝ $117.007/1/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/29/2026CYTKCytokinetics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$69.00 ➝ $115.006/24/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$172.00 ➝ $124.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$88.04M114.11N/AN/A($5.39) per share-14.98IMNMImmunome$6.94M362.43N/AN/A$5.75 per share3.86KRYSKrystal Biotech$389.13M25.39$7.29 per share45.98$42.06 per share7.97NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)IMNMImmunome-$212.39M-$2.38N/AN/AN/AN/A-51.15%-47.32%8/5/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4844.8136.04N/A53.92%19.25%17.62%8/3/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)Latest IMNM, CYTK, NUVL, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026CYTKCytokinetics-$1.63N/AN/AN/A$17.59 millionN/A8/6/2026Q2 2026NUVLNuvalent-$1.44N/AN/AN/A$0.25 millionN/A8/5/2026Q2 2026IMNMImmunome-$0.51N/AN/AN/A$0.17 millionN/A8/3/2026Q2 2026KRYSKrystal Biotech$1.70N/AN/AN/A$121.83 millionN/A5/12/2026Q1 2026IMNMImmunome-$0.60-$0.48+$0.12-$0.48$0.22 millionN/A5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.214.21IMNMImmunomeN/A21.6821.68KRYSKrystal BiotechN/A9.469.06NUVLNuvalentN/A16.1416.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AIMNMImmunome44.58%KRYSKrystal Biotech86.29%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%IMNMImmunome7.21%KRYSKrystal Biotech13.10%NUVLNuvalent5.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.43 million121.20 millionOptionableIMNMImmunome40113.25 million105.09 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableIMNM, CYTK, NUVL, and KRYS HeadlinesRecent News About These CompaniesWalleye Capital LLC Buys 33,917 Shares of Nuvalent, Inc. $NUVLJuly 23 at 6:39 AM | marketbeat.comFifth Third Bancorp Acquires New Holdings in Nuvalent, Inc. $NUVLJuly 22, 2026 | marketbeat.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)July 21, 2026 | globenewswire.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Hold" by BrokeragesJuly 20, 2026 | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Hold" from AnalystsJuly 20, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Upgraded to Sell at Wall Street ZenJuly 18, 2026 | americanbankingnews.comWall Street Zen Upgrades Nuvalent (NASDAQ:NUVL) to SellJuly 18, 2026 | marketbeat.comNuvalent Analyst Ratings and Price Targets | NASDAQ:NUVL | BenzingaJuly 17, 2026 | benzinga.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)July 16, 2026 | globenewswire.comGSK Pays $10.6 Billion for Nuvalent to Accelerate Lung Cancer PushJuly 15, 2026 | tipranks.comNuvalent (NASDAQ:NUVL) Hits New 52-Week High - Here's What HappenedJuly 14, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Insider Sells 2,111 SharesJuly 11, 2026 | insidertrades.comCandriam S.C.A. Raises Position in Nuvalent, Inc. $NUVLJuly 11, 2026 | marketbeat.comInsider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 2,111 Shares of StockJuly 10, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells 30,000 Shares of StockJuly 9, 2026 | insidertrades.comBiotech rally rests on fundamentals, M&A appetite, says ROTY's FaisonJuly 9, 2026 | msn.comAlexandra Balcom Sells 11,430 Shares of Nuvalent (NASDAQ:NUVL) StockJuly 7, 2026 | insidertrades.comShareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public ShareholdersJuly 2, 2026 | globenewswire.comNuvalent, Inc. (NASDAQ:NUVL) Short Interest UpdateJuly 1, 2026 | marketbeat.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC),June 30, 2026 | globenewswire.comBernstein Sticks to Its Buy Rating for Nuvalent (NUVL)June 25, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNM, CYTK, NUVL, and KRYS Company DescriptionsCytokinetics NASDAQ:CYTK$80.74 -1.18 (-1.44%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$80.73 -0.01 (-0.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Immunome NASDAQ:IMNM$22.21 +0.20 (+0.91%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$22.26 +0.05 (+0.23%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Krystal Biotech NASDAQ:KRYS$335.19 +7.69 (+2.35%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$339.01 +3.82 (+1.14%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$123.96 0.00 (0.00%) As of 07/16/2026Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
